Nippon Boehringer Ingelheim Co., Ltd.
ThinkPark Tower, 2-1-1, Osaki, Shinagawa-ku Tokyo 141-6017
Value t h ro ugh In n o vat io n
2010.06 Unauthorised use or reprint of text or images contained in this document is prohibited without obtaining prior permission.
COR P OR AT E PROF I L E
We have committed ourselves
to the goal of serving humankind
through development of innovative drugs .
Nearing the summit.
Taking composed and steady steps up the gently sloping hill.
Being able to breathe deeply. Walking without shortness of breath.
Feeling enjoyment and happiness at being able to do my ordinary routine.
Focusing on patients’ needs and discovering new treatments, Boehringer Ingelheim
has committed itself to research into diseases and the development of innovative,
new drugs and therapies.
An innovative remedy from Boehringer Ingelheim contributes
to the treatment of COPD (Chronic Obstructive Pulmonar y Disease).
Va l u e t h ro u g h I n n ova t i o n
“Value through Innovation” (VTI) is the vision of Boehringer Ingelheim and Lead & Learn outlines ways in which we realise and deliver VTI.
It has helped us build on our strength, make the most of our distinctive character and achieve sustainable, organic growth for every employee
and for Boeh ringer Ingelheim.
COR P OR AT E PROF I L E
Comments from the field where Lead & Learn is put into practice
Lead & Learn
Lead & Learn outlines in which we realise
and deliver Value through Innovation
Lead & Learn is about us, the people at Boehringer Ingelheim.
It is about how we work together. It also serves as a guideline for employment, evaluation, education, and training
and is the core of our corporate culture.
All of our training courses enable employees to acquire I truly think that the daily practice of Lead & Learn is I keep in mind to create a workplace in which team
practical skills. CDPS training in particular made me a shortcut to reaching my ideal of what I would like members can fully develop a personality for business
realise that global strategies filtered down to all MRs to become in the future. My current goal is to be a and strengthen their competitiveness. I would like
once I had the chance to analyse our strategies from positive influence on MRs around me. Through work to take the initiative to give constant support and
the regional manager’s point of view. Working as an and training, I came to realise my interest in people. guidance to each member so that they can realise
MR at Boehringer Ingelheim is a rewarding job that I am determined to improve my people skills and get their individual goals. Developing people also means
allows self development and growth. I would like to involved in any work that leads me to expand my own developing myself. I will strive to interact with as many
accumulate a wide variety of experiences through possibilities as well as those of the organisation. people as possible and continue to learn from them.
polishing my sales skills and preparing myself to work (Atsushi Takahashi, joined in 1999) (Shoji Hanbe, District Manager, joined in 1991)
on a global basis in the future.
(Masaru Tsuyoshi, joined in 2002)
Four Questions We Always Ask Ourselves Human Resource Development Based on
Lead & Learn External Recognition of Human
“Lead” in “Lead & Learn” means standing up for what we Resource Development
Boehringer Ingelheim is developing an environment to promote
believe in and inspiring others to do the same. “Learn” means Our workplace env ironment and human
a broad sense of knowledge and nurture the entrepreneurial resource development systems based on
looking to each other and to the market for knowledge and ideas
spirit for taking the initiative. Within this environment, free Lead & Learn have received a high level of
to develop new and better ways. appreciation from external institutions.
and open discussion is encouraged and employees build their
In order to see if we are living up to these fundamentals, we ● Selected as one of the best companies in a survey by
skills through training and work. Our vision builds a corporate the Great Place to Work® Institute Japan (2010)
ask ourselves the following four questions:
●Awarded with “JMA HRD Excellence Award” by the
culture focused on continuous innovation in all areas and gives Japan Management Association (2009)
employees direction. ● Inducted into the Balanced Scorecard* Hall of Fame
for executing strategy as the first R&D based pharmaceutical
Four questions we always ask Ourselves Our employees are the “greatest eternal asset” in our company (2007)
company. They are fully provided with opportunities to develop *Balanced Scorecard is a new management system in which strategies are
●Are we taking the initiative? cascaded down and executed using a Strategy Map based on an organisation’s
themselves as professionals. This is exemplified by our training vision and mission. The progress of the strategies is managed and monitored
●Are we connected? by the Balanced Scorecard.
system, which includes introduction training to attain the
●Are we growing together?
business manner and professional skill to perform immediately
●Are we getting results?
after job assignment and the Career Step Programme that
improves abilities required at each position layer.
For those employees who proactively commit to challenges
Lead & Learn will become our daily reality only when individual
and would like to think and act globally, many opportunities
employees share results, experiences, and ideas and put them
sponsored by Boehringer Ingelheim are offered, such as CDPS
(Career Development Programme for Sales), an MR course for
creating next-generation leaders.
COR P OR AT E PROF I L E
Past, Present, and Future…
As a Successful Company
that Continues to Grow
Ever since its foundation in 1885, Boehringer Ingelheim has been built upon its continuous success as a pharmaceutical company.
Boehringer Ingelheim has been widely acknowledged as a company trusted and relied upon by customers and as a company
that globally operates its business based on its beliefs and distinctive character.
Building on our experiences and achievements as a family-owned company, we intend to remain independent and are consistently
oriented towards long-term, sustainable, organic growth.
We Are a Globally Operating Pharmaceutical Company
Dedicated to Research and Development
Targeting Long-Term Sustainable Organic Serving Humankind through Research
Growth as a Family-owned Company into Diseases and Innovative Medicine
Boehringer Ingelheim is a pharmaceutical company with a
tradition dating back 125 years of history. It has grown into Boehringer Ingelheim is committed to the goal of serving
one of the top 20 global companies and has more than 40,000 humankind through research into diseases and the development
employees in over 140 affiliated companies worldw ide. of innovative drugs and therapies of human pharma and
Boehringer Ingelheim is also recognised as a leading company animal health. As a research-driven pharmaceutical company,
in biopharmaceuticals. Boehringer Ingelheim is engaged in worldwide drug discovery
We maintain our position as a family-owned company activ ities w ith its four main research facilities and two
and have continuously grown, making sustainable, steady supporting sites, including Japan.
development. We have achieved stronger grow th than the global
In Japan, Boehringer Ingelheim is engaged in the business pharmaceutical market over the past decade and now possess
operations of Prescription Medicine, Consumer Health Care, a well-filled, highly promising pipeline.
and Animal Health through its respective companies of Nipppon
Boehringer Ingelheim, SSP, Boehringer Ingelheim Vetmedica Japan,
and Boehringer Ingelheim Seiyaku as a manufacturing company.
B I J E C ( B I J a p a n Exe cu t i ve Commi t te e )
From the right:
Dr. Thomas Heil
Dr. Bruce Quinn
Dr. Gerhard Koeller
Dr. Yoshiki Nishikawa
Dr. Thomas Kuerner
COR P OR AT E PROF I L E
Research & Development (R&D)
Targeting Six Therapeutic Areas Our Drug Discovery Centres Located
Through research and development, Boehringer Ingelheim
constantly expands its pharmaceutical portfolio by bringing Boehringer Ingelheim is conducting clinical research in over
into existence new drug candidates with true therapeutic 50 countries and has four major R&D centres supported by
benefits to patients. We are currently involved in six therapeutic two research sites, including Japan. Our global collaboration
areas and we continue our drive for research and development ensures continuing improvement of R&D productivity and is our
with the aim of establishing a position as a leading company in drive to deliver a prospective and well-balanced pipeline.
important indication areas with high medical need. As the Asian research arm, the Kobe Pharma Research
In our constant quest for innovative drug discovery, we seek Institute assumes an important role in drug formulation and
partnerships and alliances with external partners including development of the pipeline. This facility takes advantage of
academic institutes, biopharmaceutical companies, and remarkable drug formulation technologies and reflects market
emerging corporations. needs in Japan onto global drug development activities.
Vienna (Austria) Laval (Canada)
Milan (Italy) Ridgefield (US)
Kobe Pharma Research Institute
Biberach (Germany) Ridgefield (US) Kobe (Japan) Milan (Italy)
Field of research and development: Field of research and development: Support centre for molecular and Support centre for chemical
●Neurological(CNS) diseases ● Cardiometabolic diseases cellular biology and non-clinical drug synthesis:
●Cardiometabolic diseases ●Immunology development: ● Support for synthesis in
●Respiratory disease ● Non-clinical development ● Support for international drug exploratory and leading
●Non-clinical development discovery activities optimisation projects
● Early drug formulation
Vienna (Austria) Laval (Canada) ● Specific pharmacokinetic
Field of research and development: Field of research and development: investigations
●Oncology ● Infectious diseases
Our Driving Force to Create New Value
Research and development is the foundation of the success of our business and the driving force for the development of
innovative new medicines for the treatment of diseases with an unmet therapeutic need. Out of a million screened molecules,
only one has a chance to become available as a new drug.
In the search for promising new drug candidates, every day our highly qualified researchers and developers work diligently,
employing their talent as pioneers, advanced know-how of cutting-edge technology and their excellent communication skill.
COR P OR AT E PROF I L E
GMP. We also maintain strict quality checks in all manufacturing
Boehringer Ingelheim Seiyaku
processes, including all active ingredients, materials, intermediate
products, packaging materials and finished products. Additionally,
The Boehringer Ingelheim Group conducts its operations at
physicochemical and microbiological monitoring is applied to
cutting-edge manufacturing facilities around the world served
the water and all areas used for manufacturing.
by highly experienced and knowledgeable personnel.
The Quality Control group is always looking for improvement
Boehringer Ingelheim Seiyaku assumes an important role
opportunities and performs complete quality checks for all
as a strategic factory and production site in Japan and ensures
ingredients, packaging materials, bulks, and finished products
global standard pharmaceuticals through superior drug
based on in-house standards. In addition, stability tests, quality
formulation technologies and advanced facilities with thorough
confirmation, and validation tests of each product and other
various tests, such as investigations for complaint handling and
Excellent Human Resources is the Most compatibility are also conducted. In compliance with relevant
Critical Success Factor laws and regulations, the Quality Assurance group confirms the
status of manufacturing and quality controls and determines
One of our most important success factors is our people. They
the product release. By establishing this sophisticated quality
have the right business process excellence mindset to do their
management system, we incorporate all possible means to
utmost to deliver the right product at the right time. Putting
assure the quality of the products manufactured at the plant.
Lead & Learn into practice every day, they always take initiative,
lead others, and create new and better ways through learning.
Boehringer Ingelheim Seiyaku sponsors a wide range of specific
training courses, including GMP (Good Manufacturing Practice)
training and EHS (Environmental, Health and Safety) training.
Maintaining and Improving Perfect
Along with maintaining an integrated production system from
drug formulation to packaging and warehouse management,
we have established a quality control system in accordance with Boehringer Ingelheim Seiyaku (Higashine City, Yamagata Prefecture)
Human Resources and State-of-the-Art
Facilities Create Optimum Production Quality
Boehringer Ingelheim has a word-class pharmaceutical production network.
In Japan, the company is armed w ith sophisticated drug formulation technologies and state-of-the-art manufacturing
facilities operated by highly experienced personnel.
It is our mission to bring forward continuous innovation and pursue quality and compliance at the highest level.
All efforts go to providing products and services that exceed the expectations of our customers.
COR P OR AT E PROF I L E
Medical Representative (MR)
As a Best Partner for Medical Reporting,
Practitioners consulting on daily
On behalf of the company, MRs collect evaluations and
feedback from physicians, pharmacists and other medical and feedback of
practitioners in order to promote proper use of drugs, and they Strategies the medicines and Full use of the
Participation in distributing information information
also distribute precise information on the efficacy and safety of field force strategy
meetings to promote proper use of database
their company’s products. the drugs
The diverse activities of MRs are comprised of conducting
product presentations for physicians and pharmacists, Communication
With other departments
responding to inquiries from medical practitioners, preparing Supporting clinical trials
clinical references, and visiting pharmaceutical wholesalers. Surveillance
MRs Develop Themselves through
Relationships with Customers Qualities required for MR
Each MR is expected to attain a high level of academic
In order to achieve their own cont inuous grow th and
knowledge and ethics. MR activ ities are ver y much
development as well as that of the company, Boehringer at the discretion of the indiv idual and thus require
Ingelheim MRs act in a spirit of entrepreneurship to lead others aspiration and strong self-discipline.
Boehringer Ingelheim’s MRs are expected to put
and find new ideas through their daily work. A wide range of
Value through Innovation into practice. In other words,
in depth knowledge and sophisticated communication skill being an MR requires integrity to live up to promises
cultivated through internal relationships and externally with and fulfil responsibilities, tenacious action to respond
to the needs of customers and achieve goals, high
medical practitioners enable them to do their best and take
In addition to committing myself as an MR to deliver level communication skill to bring results as a team,
medical information, I am also engaged in activities in on higher challenges. MRs take pride and fulfilment in being
flexibilit y to adapt to new env ironment, and strong
the local community, participating in the figure skating
part of medical care and contributing to human health through motivation to voluntarily address challenges.
competition of the National Athletic Meet as a female
single skater representing Nagano Prefecture. Common exceeding expectations in every activity.
to both activities is the fact that daily efforts lead to
great results. I’d like to continue to surpass expectations
in both my work and my personal goals and activities.
(Kaori Takeda, joined in 2008)
Building Trust through Activities
that Exceed Expectations
Representing Boehringer Ingelheim, MRs prov ide pharmaceutical information at the frontline to the field of medical
treatment. MRs take independent responsibilities based on their own judgment, look into the future with confidence, and are
unyielding in achieving their targets. They take great pride in Boehringer Ingelheim’s products and are always aware of the
joy and responsibility of contributing to patients’ health and well-being.
COR P OR AT E PROF I L E
Focusing on Developing Innovative Medicines
Our business consists of Prescription Medicines, Consumer Health Care, Animal Health, and Pharma Chemicals.
We take pride and joy in responding to various customer needs and contributing to humankind with our excellence in medical,
marketing and production expertise.
Our Business Prescription Medicines
Nippon Boehringer Ingelheim
Focusing on innovative drugs and treatments that represent major
therapeutic advances, Boehringer Ingelheim has established its
position as a global brand in various business and therapeutic
Growing with Innovative Prescription Medicines Focusing on the Needs of Patients
areas. We have secured a leading position in biopharmaceuticals
with our excellence in innovation and technology. Boehringer Ingelheim’s innovative medicines have been overseas. Such trials include ONTARGET® to study the efficacy
Our prescription medicine business has established a firm reaching patients around the world. Products with highly of the long-term administration of telmisartan (Micardis®),
global position and is continuing to grow steadily. In addition, reliable evidence, such as Micardis® for the treatment of UPLIFT® for tiotropium (Spiriva®), and RE-LY® to study the safety
we possess a prospective pipeline that will lead us to further essential hypertension, Spiriva® for the treatment of COPD, and and efficacy of Dabigatran (oral anticoagulant). Furthermore, we
future success. Bi-Sifrol® for the treatment of Parkinson’s disease and restless have a prospective pipeline that allows us to lead to continuous,
In Japan, SSP is responsible for the Consumer Health Care legs Syndrome (RLS), are distributed in the Japanese market organic growth.
segment and focuses mainly on over-the-counter (OTC) medicines. which is one of the most important markets. Our steady investment in R&D is substantial and it
In the field of Animal Health, we provide innovative vaccines We continue to evaluate the efficacy and safety of existing corresponds to one-fifth of net sales. Clinical trials of innovative
and treatments driven by our global R&D power to contribute to products and conduct clinical trials involving tens of thousands compounds from our own research are in progress in Japan,
the health and happiness of animals and people. of patients globally. Large-scale clinical trials have gained a including Dabigatran, DPP-IV inhibitor for type 2 diabetes, and
Pharma Chemicals is accountable for import, marketing, high level of evaluation from medical professionals in Japan and a number of oncology compounds.
and sales of active pharmaceutical ingredients and inter-
mediates, as well as promotion of custom production for
Japanese industrial customers. In addition, our operation
division manufactures our company products using our global
production network, and assumes an important and strategic
Serving Humankind with Innovative Medicines
role as a production site in Japan.
Chronic Obstructive Pulmonary Disease (COPD) is the lifestyle-attributed lung disease chiefly caused by
Partnering is an integral part of the company’s business
cigarette smoking. It is estimated that more than five million Japanese people over forty years of age suffer
strategy. The Head Office, as the centre of operations, seeks from COPD. Spiriva＠ has a positive impact on the clinical course of COPD, helping to change the way patients
global licensing agreement opportunities with innovative live with their disease.
partners around the world.
COR P OR AT E PROF I L E
C onsumer He alth C are A nimal He alth Pharma Chemic als
Boehringer Ingelheim Vetmedica Japan Nippon Boehringer Ingelheim
Bringing Groundbreaking OTC Drugs Leading Provider of Innovative Vaccines Pursuing Customer Satisfaction with Over a Century
for the Improvement of Health and Therapies for Animals of Expertise and Experience
While both the government and the private general fatigue remedy, and “Surulac” For more than 50 years, the Animal Health and respiratory syndrome (PRRS), and As the Japanese representative, Pharma Throughout its more than 100 years of
sector promote self-medication in which constipation reliever. These trusted brands business has been providing solutions for Ingelvac® M.hyo, a single shot mycoplasma Chemicals is responsible for marketing, history, customer satisfaction has been the
consumers manage their own health and are gaining trust and popularity amongst the prevention and treatment of diseases hyopneumoniae vaccine. We also specialise import sales, and outsourced production central focus of Boehringer Ingelheim. By
prevent disease, the consumer health care the people of Japan. in animals. Its business has developed in the cattle and poultry businesses. op er at ions of me d ic ine and me dic al having state-of-the-art research facilities,
market in Japan is expected to develop and Placing first priority on the health and in more than 60 countries and has been In the field of companion animals, intermediates manufac tured at the extremely flexible and versatile production
further mature in the future. happiness of customers and improving one of the fastest-growing international we address solutions to create longer and B o ehr inger Inge lhe im Gr oup’s c GMP equipment, and strict quality standards, we
In Japan, SSP Co., Ltd which joined their quality of life, SSP continues to companies, becoming one of the top 10 healthier lives for our four-legged friends. compliant factories in Germany, Italy, Spain, are capable of responding to a wide range
BI Japan group of companies in 2001 is carry out boundless research and forge companies in the animal health industry. Ever since its launch in February 2008, and the US. Boehringer Ingelheim is a leading of customer needs from research-led start-
in charge of the consumer health care new challenges. Through the Boehringer Boehringer Ingelheim Vetmedica Japan Vetmedin®, a break through treatment company that manufactures high quality ups to the major pharmaceutical groups.
business. Ingelheim Group global network, the (B I V J) is c onduc t ing animal he al t h for congestive heart failure in dogs, has pharmaceutical ingredients that comply with Taking full advantage of our global
Ever since its foundation in 1765, SSP company secures the newest seeds and operations in Japan. become the market leader in medicines or exceed pharmacopeias worldwide. logistics and sales network as well as our
has contributed to improving national information in order to strengthen its In the f ield of livestock farming, for circulatory systems of dogs and our We manufacture and supply innovative expertise in regulations and technologies,
health as one of the leading Japanese proprietary technology. we concentrate on the improvement of main product at present. This is in addition products in the fields of phytochemical (a our Pharma Chemicals customers trust
pharmaceutical companies. Under the SSP philosophy of becoming productivity and profitability of farms. to Metacam®, our non-steroidal anti- chemical substance obtained by isolating Boehringer Ingelheim as a highly
With its excellent capability to develop a reliable and friendly guarantor of health Our innovative information and support inflammatory drug, and Viacutan® Plus, and refining plant-derived components), competent partner to deliver the precise
innovative products and technologies for care, SSP has committed itself to being services have led us to become the market feed supplement which contains GL A organic chemical synthesis, and medical support they require globally to ensure
drug formulation, SSP has created a wide a “cus tome r- or ie nte d” bus ine s s by leader of swine vaccines since 2008. In essential fatty acid supplement with natural biodegradable polymers. value creation.
range of products tailored to the needs providing pharmaceuticals that support March 2008, we launched in Japan the antioxidants for dogs and cats. The sound Drug Development Process
of various life styles and stages. Major an ideal lifestyle for all individuals. first preventive vaccine against diseases expertise in scientific research at Boehringer
Exploration Approval and
New Clinical trials Product
brands include “Eve” analgesic/antipyretic associated w ith porcine circov irus 2 ingelheim allows BIVJ to deliver a wide of chemical
planning for launch
and “S. Tac” general cold remedy, “S. callled Ingelvac® CircoFLEX. Our other range of innovating products to the benefit
Compound development Process development Manufacturing
Cup” energy drink, “Hythiol-C” chloasma/ main products are the patented Ingelvac®, of both animals, and ultimately, humans.
Boehringer Ingelheim Pharma Chemicals provides innovative solutions for industrial customers.
PRRS vaccine for porcine reproductive
COR P OR AT E PROF I L E
Are we ...
Living Our Values
Our Caring Culture
of Responsibility and
Corporate Responsibility has been an integral part of our corporate culture for more than 100 years. We seek to foster economic and
social well-being in the countries and communities where we do business. Our activities therefore emanate from our operating units
in each country and embrace patients and neighbouring communities in society at large.
We strive to fulfil our mission to serve humankind through a broad range of social activities reflecting our strengths as a
Viramune® Donation Programme its mission of development of basic science as one of its social
Commitment to Combating Mother-to- contributions. We believe that scientists who build a bridge to
Child Transmission of AIDS basic research and science can support the development of
R&D in the pharmaceutical industry. We encourage excellent
B o ehr inger Inge lhe im share s t he v ie w t hat ac c e s s to activities of researchers who turn their curiosity into science,
medicines saving human lives should not be limited to those recognising these efforts through the “Baelz Award” and the “BI
who can afford them. Based on this policy, we have been Pharmacist Award” in Japan.
donating our non nucleoside reverse transcriptase inhibitor
Environment, Health, and Safety (EHS)
Viramune®*(nevirapine) to target the prevention of mother-to-
child transmission of the HIV-1 virus in countries most in need. As written in the stated core principles "Leitbild" of Boehringer
In addition to the Viramune® Donation Programme, Boehringer Ingelheim, the health and safety of our employees and the
Ingelheim with four major pharmaceutical companies and five protection of the environment has a very high priority, a fact also
UN organisations have allied to supply drugs to developing
countries at prices lower than those of developed countries.
underlined by our principles on Environmental Health & Safety
(EHS). Based on these principles, we are focusing on reducing
taking the initiative?
*A non-nucleoside reverse transcriptase inhibitor, a product of original research at Boehringer
Ingelheim. In Japan, it is not permitted to use Viramune® to prevent maternal infection.
energy consumption and CO2 emissions by introducing energy
efficient equipment, environmental emissions control, and
improvement of recycling rates. The quality and achievement of
Supporting Researchers to Turn Curiosity
these programmes are regularly checked through internal and
As an R&D-driven company, Boehringer Ingelheim addresses getting results?
For further details of our Caring Culture activities, please visit the Boehringer Ingelheim Japan website at
Lead & Learn ABCD